Kyung Dong Pharmaceutical Co Ltd

Kyung Dong Pharmaceutical maintains a conservative capital structure with a debt-to-equity ratio of 0.2, significantly below the median for the Pharmaceuticals industry. The company holds KRW 31.8 billion in cash and equivalents, but its free cash flow is negative at KRW -17.0 billion, driven by capital expenditures of KRW -20.5 billion. The liquidity risk is moderate, with a current ratio of 1.62, but net cash is negative after subtracting total debt. Profitability metrics show mixed performance. Return on equity (ROE) of 3.73% and return on assets (ROA) of 2.65% are below the industry median for Pharmaceuticals, which typically exceeds 5% ROE. Gross margin of 59.3% (KRW 116.5 billion gross profit on KRW 196.3 billion revenue) is in line with sector norms, but operating margin of 3.6% is weak compared to the 5-7% range for peers. Revenue is concentrated across three segments: Pharmaceuticals (core circulatory, blood pressure, digestive, and psychotropic drugs), Leasing (office building rentals), and Other (golf equipment, health foods, and solar power). The Pharmaceuticals segment is the largest contributor, but the Other segment's diversification into non-core businesses raises questions about strategic focus. Growth trajectory is modest. Revenue of KRW 196.3 billion in the latest period shows no clear YoY acceleration. Analysts report last actual revenue at KRW 176.5 billion, but discrepancies in data processing obscure precise growth rates. The company's capital expenditures suggest ongoing investment in infrastructure, but free cash flow remains negative. Risk factors include moderate liquidity pressure from negative free cash flow and a key flag of negative net cash after debt. Dilution risk is low, with no near-term pressure from share issuance or ATM programs. However, the company's reliance on pharmaceuticals exposes it to regulatory and pricing pressures in the healthcare sector. Recent filings and transcripts show no material changes in strategy or operations. The company continues to operate its three segments with no disclosed major restructuring. The solar power and health foods businesses remain small contributors to overall revenue.